iRhythm Technologies (NASDAQ:IRTC) Releases Earnings Results, Beats Expectations By $0.62 EPS

iRhythm Technologies (NASDAQ:IRTC) posted its quarterly earnings data on Thursday. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.62, FiscalAI reports. The business had revenue of $224.17 million for the quarter, compared to analyst estimates of $219.30 million. iRhythm Technologies had a positive return on equity of 10.81% and a negative net margin of 1.69%.The company’s revenue was up 20.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.32) earnings per share.

Here are the key takeaways from iRhythm Technologies’ conference call:

• Q2 revenue rose 20.1% to $224.2 million, marking the seventh consecutive quarter of more than 20% growth. Adjusted EBITDA margin reached 19.3%, free cash flow was a record $37.5 million, and adjusted net income improved to $19.3 million.
• iRhythm raised its 2026 outlook to $880 million-$890 million in revenue and a 13%-14% adjusted EBITDA margin, citing sustained volume growth, operating efficiencies, and disciplined expense management.
• The pending VitalConnect acquisition is intended to broaden iRhythm’s MCT offering and add capabilities in inpatient monitoring, hospital-to-home care, remote patient monitoring, and multi-vital sensing. Management expects revenue contribution beginning in 2027 and believes the combined company can reach its previously stated 15% adjusted EBITDA margin target in 2027.
• FDA clearance of iRhythm’s third-generation algorithm could reduce technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over five years after its planned first-half 2027 launch.
• Key execution and regulatory risks remain, including the pending FDA warning-letter resolution, HSR review and integration of VitalConnect, and continued uncertainty around the timing of Zio MCT clearance. The company also agreed to pay $50 million to settle litigation with Baxter, while a June cybersecurity incident involved data exfiltration despite no reported material operational or financial impact.

iRhythm Technologies Price Performance

Shares of NASDAQ IRTC opened at $127.84 on Friday. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17. iRhythm Technologies has a fifty-two week low of $100.85 and a fifty-two week high of $212.00. The firm has a market capitalization of $4.20 billion, a PE ratio of -297.30 and a beta of 1.30. The stock’s 50-day simple moving average is $115.03 and its 200-day simple moving average is $124.57.

Insider Transactions at iRhythm Technologies

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar purchased 5,312 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $10.71 per share, with a total value of $56,891.52. Following the completion of the acquisition, the director directly owned 25,611 shares of the company’s stock, valued at $274,293.81. This trade represents a 26.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IRTC. Measured Wealth Private Client Group LLC acquired a new stake in iRhythm Technologies during the 3rd quarter worth $30,000. Employees Retirement System of Texas acquired a new stake in shares of iRhythm Technologies in the 3rd quarter valued at about $36,000. Smartleaf Asset Management LLC grew its stake in iRhythm Technologies by 63.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 323 shares of the company’s stock worth $58,000 after buying an additional 125 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new position in iRhythm Technologies during the 3rd quarter worth approximately $69,000. Finally, Kestra Advisory Services LLC acquired a new position in iRhythm Technologies during the fourth quarter worth approximately $71,000.

Wall Street Analysts Forecast Growth

IRTC has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating on shares of iRhythm Technologies in a research note on Monday, June 1st. Weiss Ratings upgraded iRhythm Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Wells Fargo & Company lowered their price objective on iRhythm Technologies from $180.00 to $168.00 and set an “overweight” rating for the company in a research report on Friday. Needham & Company LLC lowered their price objective on iRhythm Technologies from $255.00 to $192.00 and set a “buy” rating for the company in a research report on Friday. Finally, BTIG Research restated a “buy” rating and set a $185.00 target price on shares of iRhythm Technologies in a research note on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $179.36.

iRhythm Technologies News Summary

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Strong Q2 results: iRhythm reported adjusted earnings of $0.58 per share, versus the consensus estimate of a $0.04 loss, while revenue rose 20.1% year over year to $224.17 million, exceeding the $219.30 million estimate. iRhythm Holdings Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VitalConnect acquisition expands addressable market: The company agreed to acquire privately held VitalConnect for $287.5 million. The deal would add wearable biosensors and broaden iRhythm’s cardiac-monitoring platform across ambulatory, inpatient and hospital-to-home settings, with closing expected by year-end. iRhythm to Buy VitalConnect for $287.5 Million
• Positive Sentiment: Raised financial ambitions: iRhythm projected 2026 revenue of $880 million to $890 million and is targeting a 13% to 14% adjusted EBITDA margin, signaling confidence in continued growth and operating leverage. iRhythm Outlines 2026 Revenue Outlook
• Neutral Sentiment: Legal overhang may be reduced: A federal court approved a proposed class-action settlement involving purchasers of iRhythm common stock. The settlement could reduce litigation uncertainty, although the articles do not specify its financial impact. Proposed iRhythm Class-Action Settlement
• Negative Sentiment: Lower valuation support from Wells Fargo: Wells Fargo reduced its price target from $180 to $168, though it maintained an “overweight” rating and still implied substantial upside. The cut may have contributed to near-term caution.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.